MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

A

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

A

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

A

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

A

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

A

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

Search

Aclaris Therapeutics Inc

Open

1.34 6.35

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

1.23

Max

1.34

Schlüsselkennzahlen

By Trading Economics

Einkommen

-89M

-97M

Verkäufe

4.9M

9.2M

EPS

-1.01

Gewinnspanne

-1,048.225

Angestellte

61

EBITDA

-4.4M

-14M

Empfehlungen

By TipRanks

Empfehlungen

Starkes Kaufsignal

12-Monats-Prognose

+628.35% upside

Dividenden

By Dow Jones

Nächstes Ergebnis

6. Mai 2025

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

-86M

123M

Vorheriger Eröffnungskurs

-5.01

Vorheriger Schlusskurs

1.34

Technischer Score

By Trading Central

Vertrauen

Very Strong Bullish Evidence

Aclaris Therapeutics Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

22. Apr. 2025, 12:21 UTC

Wichtige Markttreiber

Aclaris Therapeutics Shares Rise After FDA Clear ATI-052 for Trial

16. Juli 2024, 20:04 UTC

Akquisitionen, Fusionen, Übernahmen

Aclaris Therapeutics Received $26.5 M Upfront Plus Is Eligible for Up to $5M in Milestones >ACRS

16. Juli 2024, 20:03 UTC

Akquisitionen, Fusionen, Übernahmen

Aclaris Sells Portion of Future Royalty Payments and Milestones From Eli Lilly on Sales of OLUMIANT for Alopecia Areata to OMERS

Peer-Vergleich

Kursveränderung

Aclaris Therapeutics Inc Prognose

Kursziel

By TipRanks

628.35% Vorteil

12-Monats-Prognose

Durchschnitt 9.25 USD  628.35%

Hoch 15 USD

Tief 2 USD

Basierend auf 5 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Aclaris Therapeutics Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Starkes Kaufsignal

5 ratings

4

Buy

1

Halten

0

Sell

Technischer Score

By Trading Central

1.12 / N/AUnterstützung & Widerstand

Kurzfristig

Very Strong Bullish Evidence

Mittelfristig

Bearish Evidence

Langfristig

Strong Bearish Evidence

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über Aclaris Therapeutics Inc

Aclaris Therapeutics, Inc. a clinical-stage biopharmaceutical company, engages in the development of novel drug candidates for immune-inflammatory diseases in the United States. The company operates through two segments, Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing therapies to address significant unmet needs for immuno-inflammatory diseases. The Contract Research segment provides laboratory services. It develops Zunsemetinib (ATI-450), an MK2 inhibitor which is under Phase 1b/2 trials for the treatment of metastatic breast and pancreatic cancer; ATI-1777, a soft JAK 1/3 inhibitor, completed Phase 2b trails for the treatment of moderate to severe atopic dermatitis and other dermatologic conditions; and ATI-2138, an oral covalent inhibitor of ITK and JAK3 inhibitor under Phase 1 trials as a treatment for T cell-mediated autoimmune diseases. The company was incorporated in 2012 and is headquartered in Wayne, Pennsylvania.